Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

The system is expected to strengthen into a tropical storm by the end of the day and continue strengthening if it remains ...

Produced by LAN Studio, Link Click season 2 was one of the eagerly anticipated sequels of this year. While the latest installment of this Chinese donghua concluded on September 22, 2023 ...

A new study has found that weight loss drugs Ozempic and Wegovy have another proven benefit. Emory University's Dr. Neil Winawer sits down with Alyse Eady to examine the study's findings.

Novo Nordisk NVO is expected to beat estimates when it reports third-quarter 2024 results on Nov. 6, before the opening bell.

The obesity medicines market has so far been dominated by Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Zepbound, noted Bloomberg, which also points out that Viking Therapeutics (VKTX ...

Wegovy may significantly reduce hospital admissions for any cause and overall length of stay, according to a new analysis of data from Novo Nordisk's phase 3 SELECT trial. Compared to patients ...

SAN ANTONIO — Treatment with once-weekly semaglutide 2.4 mg (Wegovy) significantly reduced hospital admissions for all causes — not just cardiac — and overall hospitalization time in people ...

BIGBANG’s G-Dragon is back—and topping music charts across the globe! On October 31 at 6 p.m. KST, G-Dragon made his long-awaited solo return with his new pre-release single “POWER.” ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss medication Wegovy -- had a nearly 14% decrease in their body weight after ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several ...